These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 29959610)

  • 1. Economic evaluation of micafungin versus liposomal amphotericin B (LAmB) for treating patients with candidaemia and invasive candidiasis (IC) in Turkey.
    Neoh CF; Senol E; Kara A; Dinleyici EC; Turner SJ; Kong DCM
    Eur J Clin Microbiol Infect Dis; 2018 Sep; 37(9):1777-1784. PubMed ID: 29959610
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Economic evaluation of micafungin vs. liposomal amphotericin B (LAmB) for the treatment of candidaemia and invasive candidiasis (IC).
    Neoh CF; Liew D; Slavin MA; Marriott D; Chen SC; Morrissey O; Stewart K; Kong DC
    Mycoses; 2013 Sep; 56(5):532-42. PubMed ID: 23496163
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacoeconomic evaluation of micafungin versus caspofungin as definitive therapy for candidaemia and invasive candidiasis (IC) in Turkey.
    Neoh CF; Senol E; Kara A; Dinleyici EC; Turner SJ; Kong DCM
    Eur J Clin Microbiol Infect Dis; 2018 Mar; 37(3):537-544. PubMed ID: 29185089
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Economic evaluation of micafungin versus caspofungin for the treatment of candidaemia and invasive candidiasis.
    Neoh CF; Liew D; Slavin MA; Marriott D; Chen SC; Morrissey O; Stewart K; Kong DC
    Intern Med J; 2013 Jun; 43(6):668-77. PubMed ID: 23461421
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness analysis of anidulafungin vs fluconazole for the treatment of invasive candidiasis (IC) in Turkey.
    Neoh CF; Senol E; Kara A; Dinleyici EC; Turner SJ; Kong DCM
    Mycoses; 2017 Nov; 60(11):714-722. PubMed ID: 28699297
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of micafungin in invasive candidiasis caused by common Candida species with special emphasis on non-albicans Candida species.
    Cornely OA; Vazquez J; De Waele J; Betts R; Rotstein C; Nucci M; Pappas PG; Ullmann AJ
    Mycoses; 2014 Feb; 57(2):79-89. PubMed ID: 23786573
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of anidulafungin in confirmed candidaemia and other invasive Candida infections in Spain.
    Grau S; Salavert M; Carlos Pozo Laderas J; García Vargas M; Barrueta JA; Mir N
    J Mycol Med; 2013 Sep; 23(3):155-63. PubMed ID: 23849341
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness analysis of anidulafungin for the treatment of candidaemia and other forms of invasive candidiasis.
    Auzinger G; Playford EG; Graham CN; Knox HN; Weinstein D; Kantecki M; Schlamm H; Charbonneau C
    BMC Infect Dis; 2015 Oct; 15():463. PubMed ID: 26503366
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of micafungin for the treatment of invasive candidiasis and candidaemia in patients with neutropenia.
    Chandrasekar P; Sirohi B; Seibel NL; Hsu JW; Azie N; Wu C; Ruhnke M
    Mycoses; 2018 May; 61(5):331-336. PubMed ID: 29364548
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacoeconomic analysis of antifungal therapy for primary treatment of invasive candidiasis caused by Candida albicans and non-albicans Candida species.
    Ou HT; Lee TY; Chen YC; Charbonneau C
    BMC Infect Dis; 2017 Jul; 17(1):481. PubMed ID: 28693479
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Economic analysis of micafungin versus liposomal amphotericin B for treatment of candidaemia and invasive candidiasis in Germany.
    Cornely OA; Sidhu M; Odeyemi I; van Engen AK; van der Waal JM; Schoeman O
    Curr Med Res Opin; 2008 Jun; 24(6):1743-53. PubMed ID: 18477422
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial.
    Kuse ER; Chetchotisakd P; da Cunha CA; Ruhnke M; Barrios C; Raghunadharao D; Sekhon JS; Freire A; Ramasubramanian V; Demeyer I; Nucci M; Leelarasamee A; Jacobs F; Decruyenaere J; Pittet D; Ullmann AJ; Ostrosky-Zeichner L; Lortholary O; Koblinger S; Diekmann-Berndt H; Cornely OA;
    Lancet; 2007 May; 369(9572):1519-1527. PubMed ID: 17482982
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of de-escalation from micafungin versus escalation from fluconazole for invasive candidiasis in China.
    Chen D; Wan X; Kruger E; Chen C; Yue X; Wang L; Wu J
    J Med Econ; 2018 Mar; 21(3):301-307. PubMed ID: 29303621
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Economic impact of caspofungin as compared with liposomal amphotericin B for empirical therapy in febrile neutropenia in Australia.
    Al-Badriyeh D; Liew D; Stewart K; Kong DC
    J Antimicrob Chemother; 2009 Jun; 63(6):1276-85. PubMed ID: 19346292
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Echinocandins in the treatment of candidaemia and invasive candidiasis: clinical and economic perspectives.
    Neoh CF; Slavin M; Chen SC; Stewart K; Kong DC
    Int J Antimicrob Agents; 2014 Mar; 43(3):207-14. PubMed ID: 24670423
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness analysis of anidulafungin versus fluconazole for the treatment of invasive candidiasis.
    Neoh CF; Liew D; Slavin M; Marriott D; Chen SC; Morrissey O; Stewart K; Kong DC
    J Antimicrob Chemother; 2011 Aug; 66(8):1906-15. PubMed ID: 21628305
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacoeconomic evaluation of voriconazole vs. liposomal amphotericin B in empiric treatment of invasive fungal infections in Turkey.
    Turner SJ; Senol E; Kara A; Al-Badriyeh D; Dinleyici EC; Kong DC
    BMC Infect Dis; 2013 Nov; 13():560. PubMed ID: 24279677
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment and prophylaxis of invasive candidiasis with anidulafungin, caspofungin and micafungin and its impact on use and costs: review of the literature.
    Wilke M
    Eur J Med Res; 2011 Apr; 16(4):180-6. PubMed ID: 21486732
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacoeconomic analysis of liposomal amphotericin B versus voriconazole for empirical treatment of febrile neutropenia.
    Collins CD; Stuntebeck ER; DePestel DD; Stevenson JG
    Clin Drug Investig; 2007; 27(4):233-41. PubMed ID: 17358095
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of rapid, culture-independent diagnosis of candidaemia and invasive candidiasis in a community health system.
    Patch ME; Weisz E; Cubillos A; Estrada SJ; Pfaller MA
    J Antimicrob Chemother; 2018 Mar; 73(suppl_4):iv27-iv30. PubMed ID: 29608750
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.